AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04812860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet,Dosing frequency: once daily, Route of administration: oral
Trial: NCT00535002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00123123
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01652339
Drug: Exforge tab. 10/160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01652339
Drug: Lodivixx tab. 5/160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01740414
Drug: MN-166 (50 mg) First
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
Trial: NCT01740414
Drug: Placebo First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
Trial: NCT04475120
Drug: SOC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00536237
Drug: Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03698227
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv infusion
Trial: NCT02713945
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental drug administrated orally
Trial: NCT02713945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for the control group
Trial: NCT00880490
Drug: Inhaled PT005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, inhaled
Trial: NCT00880490
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, inhaled
Trial: NCT01641081
Drug: Foradil Aerolizer, High Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foradil Aerolizer 24 micrograms, twice per day for 14 days
Trial: NCT01641081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in the Pressair for 14 days
Trial: NCT02753426
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 20mg capsule by mouth, twice a day for 30 days.
Trial: NCT03538054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule, by mouth, twice daily every 12 hours.
Trial: NCT02753426
Drug: Placebo (for Doxycycline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
Trial: NCT02759029
Drug: eradication of Helicobacter pylori
RxNorm normalized name: Combinations for eradication of Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk
Trial: NCT00778310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
Trial: NCT02757885
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight.
Trial: NCT00701246
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00701246
Drug: placebo (folic acid)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00194727
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
Trial: NCT01345188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
Trial: NCT04255589
Drug: Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
Trial: NCT04255589
Drug: Placebo of the CKD-495 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of the CKD-495 75mg Tab.
Trial: NCT01801930
Drug: OCV-103 and OCV-104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of each
Trial: NCT01801930
Drug: OCV-103 and OCV-104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of each
Trial: NCT01801930
Drug: OCV-103 and OCV-104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of each
Trial: NCT01801930
Drug: OCV-103 and OCV-104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of each
Trial: NCT02909751
Drug: Cyclophosphamide 600 mg/m2 iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Max. 3 months
Trial: NCT04255589
Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Trial: NCT02411942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
Trial: NCT00828672
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Trial: NCT01849406
Drug: Nasal spray Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one week therapy of nasal normal saline twice per day
Trial: NCT00083525
Drug: WX-UK1 in combination with Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04444466
Drug: UCB8600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.
Trial: NCT03699904
Drug: Placebo capsules (containing Avicel blend)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
Trial: NCT02392468
Drug: Placebo matching BI 409306 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01434849
Drug: Control (placebo) group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
Trial: NCT00651885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03095508
Drug: ANTI-ANGIN® FORMULA, topical metered spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution
Trial: NCT02468141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00029380
Drug: Sangstat
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00029380
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02219490
Drug: ABT-450/r/ABT-267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use
Trial: NCT02219490
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use
Trial: NCT00679380
Drug: Entocort EC® 3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg/day, 3 mg tablets
Trial: NCT00679380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02376478
Drug: TNF-alpha inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapy for at least 6 months
Trial: NCT02376478
Drug: Purine/folic acid analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapy for at least 6 months
Trial: NCT02116361
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) injected into protocol-specified areas on Day 1.
Trial: NCT04021706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo is a inert substance
Trial: NCT02332798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00789724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
Trial: NCT00595868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same as Varenicline arm
Trial: NCT01855841
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
Trial: NCT03199144
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of Gemzar-Abraxane
Trial: NCT01756638
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
Trial: NCT04268303
Drug: Placebo Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Film for BXCL501
Trial: NCT00805818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% Injection
Trial: NCT03185923
Drug: TCM plus conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical \& Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days.
Trial: NCT03185923
Drug: TCM placebo plus conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days.
Trial: NCT00761358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02954055
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm B
Trial: NCT02954055
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm B
Trial: NCT00459264
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid oral solution 2.5mg/5ml daily for up to 3 years
Trial: NCT00459264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for folic acid oral solution (2.5mg/5ml)
Trial: NCT00361621
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously on day 1 of a 21-day cycle for 6 cycles
Trial: NCT00361621
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously on day 1 of a 21-day cycle for 6 cycles
Trial: NCT01316978
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
Trial: NCT01316978
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
Trial: NCT01316978
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
Trial: NCT04674722
Drug: Injection of 99mTc-NM-02
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
Trial: NCT04674722
Drug: Injection of 188Re-NM-02
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Patient will be injected with microdose (\<100ug) of 188Re-NM-02 radionuclide therapy
Trial: NCT01429779
Drug: Movicol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
Trial: NCT04044664
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules.
Trial: NCT00300456
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg, daily, 12 weeks
Trial: NCT00300456
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily, 12 weeks, see Arm Description for dosage information
Trial: NCT00300456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily, 12 weeks, see Arm Description for placebo information
Trial: NCT04914936
Drug: ACP-196
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.
Trial: NCT03099824
Drug: GC4711 Oral Capsule G-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 82 mg (1 capsule)
Trial: NCT03099824
Drug: IV GC4419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
Trial: NCT03099824
Drug: GC4711 Oral Capsule G-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 164 mg (2 capsules)
Trial: NCT03099824
Drug: GC4711 Oral Capsule G-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 246 mg (3 capsules)
Trial: NCT03099824
Drug: GC4711 Oral Capsule G-111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 175 mg (1 capsule)
Trial: NCT03099824
Drug: GC4711 Oral Capsule G-112
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 145 mg (1 capsule)
Trial: NCT03099824
Drug: GC4711 Oral Capsule G-119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 233 mg (1 capsule)
Trial: NCT03099824
Drug: GC4711 Oral Capsule G-125
RxNorm normalized name: Charcoaid-G 125 MG/ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 233 mg (1 capsule)
Trial: NCT03099824
Drug: IV GC4711
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
Trial: NCT01130818
Drug: GLPG0492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
Trial: NCT01130818
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral solution
Trial: NCT01130818
Drug: GLPG0492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast
Trial: NCT00852423
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
Trial: NCT03885596
Drug: CA-008
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CA-008 4.2 mg reconstituted in saline
Trial: NCT03885596
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg IV at the onset of anesthesia
Trial: NCT03885596
Drug: Acetaminophen IV
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g at the onset of anesthesia
Trial: NCT03885596
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
Trial: NCT03885596
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg PO bid each day postoperative
Trial: NCT00383188
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, once daily (QD) for 12 weeks
Trial: NCT03523962
Drug: DuraPrep
RxNorm normalized name: DuraPrep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.
Trial: NCT01611194
Drug: Sham control 1.2 atms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
Trial: NCT01053039
Drug: Intrathecal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
Trial: NCT00001146
Drug: Ethyl Eicosapentaenoic Acid
RxNorm normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00001146
Drug: OmegaBrite
FDA approved: no
EMA approved: no
PMDA approved: no